Method for administering interleukin-2

• US 4,832,686 A
• Filed: 06/24/1986
• Issued: 05/23/1989
• Est. Priority Date: 06/24/1986
• Status: Expired due to Term

• Current Assignee: Mark E. Anderson
• Original Assignee: Mark E. Anderson
• Inventors: Anderson, Mark E.
• Primary Examiner(s): Lovering, Richard D.
• Application Number:
  US06/878,026
• Time in Patent Office: 1,064 Days
• Field of Search: 604/891, 604/891.1, 604/49, 424/85, 424/426, 424/463, 424/486, 424/497, 424/85.2, 514/885, 514/965
• US Class Current: 604/500
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/204 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Abstract

A biocompatible, biodegradable, bioerodible composite polymer matrix comprising interleukin-2 in an appropriate polymer. The polymer may be a polymer or copolymer of lactic acid, lactide, glycolide, glutamic acid, or it may be collagen or albumin. The material contains from 10² to 10⁸ U IL-2/g of polymer. Also disclosed is a method for making the composite polyer matrix and a method for implanting the material. A soft, malleable controlled-release composite material may be used for intracranial or other implantation and may be shaped or molded to fit the site from which malignant tissue has been removed, opposing the residual tumor, complementing hemostasis, compatible with anatomical structure, and functioning as an implantable immunotherapeutic adjuvant.

Claims

1. A method for administering interleukin-2, comprising the step of intracranially implanting into an area from which a neoplasm has been removed a controlled-release polymer matrix, comprising a biocompatible, bioerodible, hemostatic polylactic acid polymer material and interleukin-2 which material is malleable at the time of implantation.

2. The method of claim 1, wherein said neoplasm is glioblastoma.

3. The method of claim 1, further comprising the step of shaping said polymer material to fit the site from which said neoplasm was removed, thereby restoring the brain to its normal anatomical configuration.

4. The method of claim 1, wherein said polymer matrix further comprises a chemotherapeutic agent.

5. The method of claim 4, wherein said chemotherapeutic agent is a nitrosourea.

6. The method of claim 5, wherein said chemotherapeutic agent is BCNU or methyl-CCNU.

7. The method of claim 1, wherein said polymer matrix is in the form of a paste.